Palexia (Tapentadol Hydrochloride)

Tapentadol hydrochloride, the active ingredient in Palexia, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe pain in adult patients when other analgesics are inadequate. GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tapentadol hydrochloride is used in the management of pain through central nervous system pathways.

- Acute postoperative pain: provides analgesia after surgical procedures. - Chronic musculoskeletal pain: helps control persistent pain from conditions such as osteoarthritis. - Neuropathic pain associated with diabetic peripheral neuropathy: reduces pain intensity in affected patients. - Cancer‑related pain: contributes to overall pain control in oncology settings. - Severe breakthrough pain: offers rapid relief when baseline analgesia is insufficient.

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea and vomiting - Constipation - Dizziness or light‑headedness - Headache - Somnolence or fatigue - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Seizures - Severe hypotension - Serotonin syndrome (when combined with serotonergic agents) - Allergic reactions such as angio‑edema or anaphylaxis - Dependence, abuse potential or withdrawal symptoms

When prescribing Tapentadol, clinicians should consider several safety aspects.

- Assess pain severity and prior opioid exposure: ensure appropriate indication before initiating therapy. - Monitor for respiratory depression: especially during dose escalation or in patients with pulmonary disease. - Evaluate renal and hepatic function: dose adjustments may be required in impairment. - Avoid use with other central nervous system depressants: increased risk of sedation and respiratory effects. - Counsel patients on signs of dependence and proper disposal. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Tapentadol interacts with several drug classes that can modify its safety or efficacy.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - CNS depressants (benzodiazepines, barbiturates, alcohol): additive respiratory depression. - Serotonergic agents (SSRIs, SNRIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (quinidine, fluoxetine): may increase tapentadol plasma levels. - CYP3A4 inducers (rifampicin, carbamazepine): may reduce analgesic effect. - Diuretics: potential for enhanced hypotensive response. - Antihistamines: may increase sedation. - Anticonvulsants: monitor seizure threshold.